Effect of simvastatin on restenosis after percutaneous transluminal angioplasty of femoropopliteal arterial obstruction

Am J Cardiol. 2000 Oct 1;86(7):774-6, A6. doi: 10.1016/s0002-9149(00)01079-1.

Abstract

This retrospective observational intravascular ultrasound study evaluated whether simvastatin therapy limits lumen area reduction 1-year after percutaneous transluminal angioplasty (PTA) by reducing reactive plaque growth, reducing reactive vasoconstriction, or both. This study showed that plaque growth is a general response 1 year after PTA regardless of the use of simvastatin; simvastatin has the potential to induce positive vascular remodeling, thereby reducing the occurrence of restenosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Angioplasty, Balloon, Coronary*
  • Arterial Occlusive Diseases / diagnostic imaging
  • Arterial Occlusive Diseases / drug therapy
  • Arterial Occlusive Diseases / pathology
  • Arterial Occlusive Diseases / therapy*
  • Chemotherapy, Adjuvant
  • Female
  • Femoral Artery* / diagnostic imaging
  • Femoral Artery* / pathology
  • Follow-Up Studies
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Male
  • Middle Aged
  • Popliteal Artery* / diagnostic imaging
  • Popliteal Artery* / pathology
  • Retrospective Studies
  • Simvastatin / therapeutic use*
  • Ultrasonography, Interventional

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Simvastatin